[The "immune checkpoints", how does it work]. / Les « immune checkpoints ¼, comment ça marche.
Ann Pathol
; 37(1): 18-28, 2017 Feb.
Article
en Fr
| MEDLINE
| ID: mdl-28160999
ABSTRACT
Costimulatory molecules allow the full lymphocyte activation, whereas co-inhibitory molecules are negative counterparts that act as immune regulators, avoiding excessive response. In some context of chronic inflammation such as cancer, co-inhibitory immune checkpoint as CTLA-4, PD-1, Lag-3, Tim-3 can accumulate at the membrane of T cells leading to a state of anergy and therefore the loss of tumor growth control. Consequently, these immune checkpoints are considered as potential target in the treatment of cancer. Immunotherapy by anti-CTLA-4 and anti-PD-1/PD-L1 early demonstrated very good proof of efficacy in the setting of several cancers types, supporting the role of these molecules in tumor immune escape. The aim of this review is to summarize the pathophysiology of immune checkpoints and their therapeutic applications in cancer.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Activación de Linfocitos
/
Subgrupos de Linfocitos T
/
Antígeno B7-H1
/
Antígeno CTLA-4
/
Receptor de Muerte Celular Programada 1
/
Proteínas de Neoplasias
/
Neoplasias
Límite:
Humans
Idioma:
Fr
Revista:
Ann Pathol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Francia